Regulatory24 Jul 2026, 08:10 pm
Neogen Chemicals Reports No Deviation in Preferential Issue Fund Utilization
AI Summary
Neogen Chemicals Limited has submitted a revised statement of deviation/variation for funds raised through a preferential issue for the quarter ended June 30, 2026. The company confirms there has been no deviation or variation in the utilization of the ₹161 crore raised. The funds were allocated to investment in wholly-owned subsidiaries (₹100 crore), working capital requirements (₹21 crore), and general corporate purposes (₹40 crore). The utilization has been reviewed by the Audit Committee and monitored by CRISIL Ratings Limited, with no adverse comments or deviations noted.
Key Highlights
- No deviation reported in the utilization of ₹161 crore from preferential issue.
- Funds allocated to subsidiaries, working capital, and general corporate purposes.
- Audit Committee and CRISIL Ratings reviewed fund utilization.
- Statement filed as per Regulation 32 of Listing Regulations.
Price Impact
More from NEOGEN